188 Re-N-DEDC Lipiodol for Treatment of Hepatocellular Carcinoma (HCC)-A Clinical and Prospective Study to Assess In-Vivo Distribution in Patients and Clinical Feasibility of Therapy.

التفاصيل البيبلوغرافية
العنوان:	¹⁸⁸ Re-N-DEDC Lipiodol for Treatment of Hepatocellular Carcinoma (HCC)-A Clinical and Prospective Study to Assess In-Vivo Distribution in Patients and Clinical Feasibility of Therapy.
المؤلفون:	Kumar N; Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India., Gupta P; Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India., Shamim SA; Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India., Chirayil V; Bhabha Atomic Research Centre, Mumbai, Maharashtra, India., Subramanian S; Bhabha Atomic Research Centre, Mumbai, Maharashtra, India., Mallia MB; Bhabha Atomic Research Centre, Mumbai, Maharashtra, India., Bal C; Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
المصدر:	World journal of nuclear medicine [World J Nucl Med] 2023 May 01; Vol. 22 (2), pp. 114-123. Date of Electronic Publication: 2023 May 01 (Print Publication: 2023).
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Thieme Country of Publication: Germany NLM ID: 101286955 Publication Model: eCollection Cited Medium: Print ISSN: 1450-1147 (Print) Linking ISSN: 14501147 NLM ISO Abbreviation: World J Nucl Med Subsets: PubMed not MEDLINE
أسماء مطبوعة:	Publication: 2022- : [Stuttgart] : Thieme Original Publication: Vienna : World Federation of Nuclear Medicine & Biology
مستخلص:	Objective The incidence of inoperable hepatocellular carcinoma (HCC) with/without malignant portal vein thrombosis (PVT) is increasing in India for the last decade; thus, Bhabha Atomic Research Centre (BARC), Mumbai, India, developed diethydithiocarbamate (DEDC), a new transarterial radionuclide therapy (TART) agent. ¹⁸⁸ Re-N-DEDC lipiodol is an emerging radiotherapeutic agent for inoperable HCC treatment due to its simple and onsite labeling procedure, cost-effectiveness, and least radiation-induced side effects. This study aimed to evaluate in-vivo biodistribution and clinical feasibility of ¹⁸⁸ Re-N-DEDC lipiodol TART in HCC and optimization of labeling procedure to assess post-labeling stability and radiochemical yield of labeled lipiodol with ¹⁸⁸ Re-N-DEDC complex. Materials and Methods DEDC kits were obtained as gift from BARC, Mumbai. Therapy was given to 31 HCC patients. Post-therapy planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging were performed to see tumor uptake and biodistribution. Clinical feasibility and toxicity were decided by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v 5.0). Statistical Analysis Descriptive statistics was done for data using SPSS v22. Values was expressed as mean ± standard deviation or median with range. Results Post-therapy planar and SPECT/CT imaging showed radiotracer localization in hepatic lesions. Few patients showed lungs uptake due to hepato-pulmonary shunt (lung shunt < 10%). Maximum clearance was observed through urinary tract with very less elimination through hepatobiliary route due to slow rate of leaching of tracer. No patient showed myelosuppression or any other long-term toxicity over median follow-up of 6 months. Mean overall % radiochemical yield of ¹⁸⁸ Re-N-DEDC lipiodol was 86.04 ± 2.35%. The complex ¹⁸⁸ Re-N-DEDC was found to be stable at 37°C under sterile condition over a period of 1 hour without any significant change on the % radiochemical purity (90.83 ± 3.24%, 89.78 ± 3.67%, 89.22 ± 3.77% at 0, 0.5, 1 hours, respectively). Conclusion Human biodistribution showed very high retention of radiotracer in hepatic lesions with no long-term toxicity with this therapy. The kit preparation procedure is ideally suited for a busy hospital radio-pharmacy. By this procedure, ¹⁸⁸ Re-N-DEDC lipiodol can be prepared in high radiochemical yield within a short time (∼45 minutes). Thus, ¹⁸⁸ Re-N-DEDC lipiodol can be considered for TART in advanced and/or intermediate HCC. Competing Interests: Conflict of Interest None declared. (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).)
References:	Lancet Oncol. 2009 Jan;10(1):25-34. (PMID: 19095497) J Gastrointestin Liver Dis. 2010 Sep;19(3):311-7. (PMID: 20922197) Oncology. 2009;77(3-4):162-71. (PMID: 19641335) Semin Liver Dis. 1999;19(3):329-38. (PMID: 10518312) Indian J Nucl Med. 2018 Jan-Mar;33(1):1-5. (PMID: 29430106) J Hepatol. 2004 Jan;40(1):124-31. (PMID: 14672623) Front Med (Lausanne). 2019 Jun 14;6:132. (PMID: 31259173) Hepatology. 2018 Feb;67(2):600-611. (PMID: 28859220) J Nucl Med. 2003 Dec;44(12):2033-8. (PMID: 14660730) Nucl Med Commun. 2004 Jul;25(7):691-9. (PMID: 15208496) Transplant Proc. 2009 May;41(4):1260-3. (PMID: 19460533) Hepatology. 2018 Oct;68(4):1429-1440. (PMID: 29194711) Appl Radiat Isot. 2018 Jul;137:147-153. (PMID: 29625347) J Gastroenterol Hepatol. 2001 Jun;16(6):666-73. (PMID: 11422620) JAMA Oncol. 2017 Dec 1;3(12):1683-1691. (PMID: 28983565) Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):765-79. (PMID: 25827821) N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514) Chest. 2011 Jun;139(6):1463-1469. (PMID: 20947651) Appl Radiat Isot. 2007 Jan;65(1):64-9. (PMID: 17010628) J Hepatol. 2013 Apr;58(4):730-5. (PMID: 23220252) Int J Rad Appl Instrum B. 1986;13(4):465-77. (PMID: 3793504) Cancer Biother Radiopharm. 2022 Feb;37(1):63-70. (PMID: 34101501) Nucl Med Biol. 2003 May;30(4):381-7. (PMID: 12767395)
فهرسة مساهمة:	Keywords: DEDC (diethydithiocarbamate); hepatocellular carcinoma (HCC); radiochemical purity (RCP); radiochemical yield (RCY); trans-arterial radionuclide therapy (TART)
تواريخ الأحداث:	Date Created: 20230524 Latest Revision: 20230525
رمز التحديث:	20240628
مُعرف محوري في PubMed:	PMC10202571
DOI:	10.1055/s-0043-1764306
PMID:	37223628
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	1450-1147
DOI:	10.1055/s-0043-1764306